FR2445149A1 - Composition pharmaceutique ayant une activite antitumorale - Google Patents

Composition pharmaceutique ayant une activite antitumorale

Info

Publication number
FR2445149A1
FR2445149A1 FR7932054A FR7932054A FR2445149A1 FR 2445149 A1 FR2445149 A1 FR 2445149A1 FR 7932054 A FR7932054 A FR 7932054A FR 7932054 A FR7932054 A FR 7932054A FR 2445149 A1 FR2445149 A1 FR 2445149A1
Authority
FR
France
Prior art keywords
pharmaceutical composition
tumor activity
pharmacological composition
tumor
pyrexia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7932054A
Other languages
English (en)
Other versions
FR2445149B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kureha Corp
Original Assignee
Kureha Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP16138878A external-priority patent/JPS5592325A/ja
Priority claimed from JP14215279A external-priority patent/JPS5665828A/ja
Priority claimed from JP14215379A external-priority patent/JPS5665829A/ja
Application filed by Kureha Corp filed Critical Kureha Corp
Publication of FR2445149A1 publication Critical patent/FR2445149A1/fr
Application granted granted Critical
Publication of FR2445149B1 publication Critical patent/FR2445149B1/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a pour objet une composition pharmacologique ayant une activité antitumorale. Elle consiste en une substante antitumorale ayant au moins un groupe amino ou carboxyle lié par une liaison amide à un anticorps antitumoral purifie par chromatographie par affinité. Cette composition pharmacologique ne donne pas lieu à des effets secondaires, tels que pyrexie ou anaphylaxie.
FR797932054A 1978-12-29 1979-12-28 Composition pharmaceutique ayant une activite antitumorale Expired FR2445149B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP16138878A JPS5592325A (en) 1978-12-29 1978-12-29 Antitumor agent and its preparation
JP14215279A JPS5665828A (en) 1979-11-02 1979-11-02 Antitumor agent
JP14215379A JPS5665829A (en) 1979-11-02 1979-11-02 Antitumor agent

Publications (2)

Publication Number Publication Date
FR2445149A1 true FR2445149A1 (fr) 1980-07-25
FR2445149B1 FR2445149B1 (fr) 1989-12-29

Family

ID=27318393

Family Applications (1)

Application Number Title Priority Date Filing Date
FR797932054A Expired FR2445149B1 (fr) 1978-12-29 1979-12-28 Composition pharmaceutique ayant une activite antitumorale

Country Status (8)

Country Link
US (2) US4315851A (fr)
CH (1) CH655010A5 (fr)
DE (1) DE2952690C2 (fr)
FR (1) FR2445149B1 (fr)
GB (1) GB2038836B (fr)
IT (1) IT1127324B (fr)
PH (1) PH16902A (fr)
SE (3) SE7910483L (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010A1 (fr) * 1981-04-15 1982-10-22 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
FR2548901A1 (fr) * 1983-06-23 1985-01-18 Erba Farmitalia Nouveaux determinants antigeniques apparentes a l'adenocarcinome et anticorps qui leur sont specifiques, procedes pour les preparer et combinaisons de reactifs s'y rapportant
EP0122132A3 (fr) * 1983-04-08 1985-11-27 Kureha Kagaku Kogyo Kabushiki Kaisha Substance anti-tumorale
FR2584293A1 (fr) * 1985-07-04 1987-01-09 Ire Celltarg Sa Anticorps utiles comme agents de pilotage et conjugues les incorporant

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4501692A (en) * 1979-07-26 1985-02-26 Syva Company Charge effects in enzyme immunoassays
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
JPS57106625A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
JPS58116496A (ja) * 1981-12-29 1983-07-11 Nippon Kayaku Co Ltd アミドｎ置換ブレオマイシン類
JPS59116232A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体及びその製造法
JPH0651643B2 (ja) * 1983-01-19 1994-07-06 帝人株式会社 殺細胞性修飾免疫グロブリン及びその製造方法
EP0121388B1 (fr) * 1983-03-30 1990-06-13 Lilly Industries Limited Conjugués d'immunoglobuline
GB2142428A (en) * 1983-06-23 1985-01-16 Erba Farmitalia Adenocarcinoma related antigenic determinants and antibodies specific thereto
EP0250486A4 (fr) * 1986-01-03 1988-05-25 Univ Melbourne Derives de melphalan.
GB8601406D0 (en) * 1986-01-21 1986-02-26 Ucb Bioproducts Conjugate of x-melanotropine with p-l-sarcolysine
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5004606A (en) * 1986-09-24 1991-04-02 Hybritech Incorporated Non-covalent antibody-anthracycline immunocomplexes
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
DE4122210C2 (de) * 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
ATE127018T1 (de) * 1992-03-06 1995-09-15 Fiutowski Zdzislaw Pharmazeutische zusammensetzung mit antiviraler und antibakterieller wirkung.
JP2578044B2 (ja) * 1992-03-14 1997-02-05 呉羽化学工業株式会社 フェニルアラニン−グリシン誘導体、その製造方法、及びその誘導体を含有する抗腫瘍剤
US5382582A (en) * 1993-03-26 1995-01-17 Chan; Carcy L. Methotrexate analogs and methods of using same
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US6372217B1 (en) * 1997-06-03 2002-04-16 Regents Of The University Of Minnesota Methods for the treatment of CD7+ viral infection with TXU-7-PAP
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US7306919B1 (en) 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
ATE545423T1 (de) * 2002-03-18 2012-03-15 Dainippon Sumitomo Pharma Co Mittel zur behandlung von lungenkrebs
PL1670514T3 (pl) * 2003-09-25 2010-11-30 Astellas Pharma Inc Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
EP3075247B1 (fr) * 2004-02-02 2022-10-12 BioSight Ltd. Remedes conjugues de therapie et diagnostic du cancer
US7612071B2 (en) * 2004-03-12 2009-11-03 Syntrix Biosystems, Inc. Compositions and methods employing aminopterin
US20080312201A1 (en) * 2004-09-10 2008-12-18 Patrick Fogarty Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
AU2006318216C1 (en) 2005-11-28 2012-02-16 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
US7998967B2 (en) 2008-03-03 2011-08-16 Tosk, Incorporated Methotrexate adjuvants to reduce toxicity and methods for using the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2312259A1 (fr) * 1975-05-27 1976-12-24 Yeda Res & Dev Medicament anti-tumoral
FR2323147A1 (fr) * 1975-09-03 1977-04-01 Eisai Co Ltd Reactif de diagnose de neoplasme et procede de diagnose de neoplasme
US4017471A (en) * 1975-09-15 1977-04-12 G. D. Searle & Co. Immunological compounds
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT300193B (de) 1969-01-17 1972-07-10 Agricura Labor Ltd Verfahren zur Herstellung von Mastitis-Immunoglobulin
IL34079A (en) * 1969-04-01 1973-02-28 Upjohn Co Purification of ypsilon-globulins
US3917818A (en) * 1970-01-14 1975-11-04 Agricura Labor Ltd Treatment of mastitis in cows, the product for this treatment and to the production of said product
SE348942B (fr) * 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US3983001A (en) * 1972-05-10 1976-09-28 Ceskoslovenska Akademie Ved Isolation of biologically active compounds by affinity chromatography
US4160018A (en) * 1973-06-25 1979-07-03 Bjorklund Knut B Stabilized cancer associated polypeptide antigen and preparation thereof
US3947352A (en) * 1974-05-31 1976-03-30 Pedro Cuatrecasas Polysaccharide matrices for use as adsorbents in affinity chromatography techniques
GB1509707A (en) 1974-09-20 1978-05-04 Searle & Co Immunological compounds
GB1541435A (en) * 1975-02-04 1979-02-28 Searle & Co Immunological materials
US4195017A (en) * 1975-02-25 1980-03-25 Samuel Bogoch Malignin, derived from brain tumor cells, complexes and polypeptides thereof
US4263279A (en) * 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
GB1541436A (en) 1976-02-02 1979-02-28 Searle & Co Immunological materials
US4123427A (en) * 1976-07-27 1978-10-31 Daniel Thomas M Method for the purification of mycobacterial protein antigens and resulting product
IT1107772B (it) * 1977-08-22 1985-11-25 Cancer Res Inst Royal Procedimento per la produzione di complessi macromolecolari prodotto ottenuto e composizioni farmaceutiche che lo contengono come ingrediente attivo
US4228237A (en) * 1978-09-21 1980-10-14 Calbiochem-Behring Corp. Methods for the detection and determination of ligands
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4223005A (en) * 1979-02-15 1980-09-16 University Of Illinois Foundation Antibody coated bacteria

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2312259A1 (fr) * 1975-05-27 1976-12-24 Yeda Res & Dev Medicament anti-tumoral
FR2323147A1 (fr) * 1975-09-03 1977-04-01 Eisai Co Ltd Reactif de diagnose de neoplasme et procede de diagnose de neoplasme
US4017471A (en) * 1975-09-15 1977-04-12 G. D. Searle & Co. Immunological compounds
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EXBK/72 *
EXBK/73 *
EXBK/75 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010A1 (fr) * 1981-04-15 1982-10-22 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
EP0063988A1 (fr) * 1981-04-15 1982-11-03 Sanofi S.A. Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation
EP0122132A3 (fr) * 1983-04-08 1985-11-27 Kureha Kagaku Kogyo Kabushiki Kaisha Substance anti-tumorale
FR2548901A1 (fr) * 1983-06-23 1985-01-18 Erba Farmitalia Nouveaux determinants antigeniques apparentes a l'adenocarcinome et anticorps qui leur sont specifiques, procedes pour les preparer et combinaisons de reactifs s'y rapportant
FR2584293A1 (fr) * 1985-07-04 1987-01-09 Ire Celltarg Sa Anticorps utiles comme agents de pilotage et conjugues les incorporant
EP0208615A1 (fr) * 1985-07-04 1987-01-14 Ire-Celltarg S.A. Anticorps utiles comme agents de pilotage et conjugués les incorporant

Also Published As

Publication number Publication date
GB2038836B (en) 1982-11-24
PH16902A (en) 1984-04-10
SE7910483L (sv) 1980-06-30
IT1127324B (it) 1986-05-21
SE8406511L (sv) 1984-12-20
SE8406510L (sv) 1984-12-20
FR2445149B1 (fr) 1989-12-29
US4401592A (en) 1983-08-30
DE2952690C2 (de) 1984-11-08
CH655010A5 (de) 1986-03-27
SE8406511D0 (sv) 1984-12-20
IT7928464A0 (it) 1979-12-31
US4315851A (en) 1982-02-16
DE2952690A1 (de) 1980-07-03
SE8406510D0 (sv) 1984-12-20
GB2038836A (en) 1980-07-30

Similar Documents

Publication Publication Date Title
FR2445149A1 (fr) Composition pharmaceutique ayant une activite antitumorale
DK0746398T3 (da) Antistofrensning
NO943546D0 (no) Proteinrensing
FR2378027A1 (fr) Acide, ester ou amide alkyl-lactone hetero-substitue, leur obtention et leur application a la preparation de lactone-oxazolines
DE69533748D1 (de) Immunsuppressive proteinziele
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
FI963197A0 (fi) Laktoferriinin eristäminen maidosta
ATE213639T1 (de) Proteinreinigung
ES2078947T3 (es) Purificacion del complejo del factor viii utilizando cromatografia de afinidad con heparina.
ATE125269T1 (de) Radiomarkierte peptide mit antikoagulanswirkung.
BR0210386A (pt) Purificação de albumina de soro humano
WO2003107009A3 (fr) Methodes d'amelioration d'une liaison caracteristique d'une molecule
IL64292A (en) D-homoandrostane-17alpha-carboxylic acids,derivatives thereof and 17alpha-spiroethers,their manufacture and pharmaceutical compositions containing them
FR2432038A1 (fr) Conjugues marques d'hydrazide d'acide naphtalene-1,2-dicarboxylique chimioluminescent et leur procede de preparation
PT87537A (pt) Process for the preparation of cyclic anticoagulant peptides
FR2363563A1 (fr) Nouveaux derives de 1-acyloxymethyl-5-fluorouracile utiles notamment comme agents antitumoraux, et leur procede de preparation
EP0822828A4 (fr) Isolation d'une proteine de 55 a 75 kd qui se lie a une proteine de prion
FR2575466B1 (fr) Nouveaux complexes de silicium hexacoordines, leur procede de preparation et leur application
NO904292L (no) Fremgangsmaate for fremstilling av antikoagulerende peptider.
DE68916850D1 (de) Antikoagulierende Peptid-Alkohole.
FI813929L (fi) Foerfarande foer avskiljande av asylerade fosfolipider fraon dessa innehaollande fosfatidyl-olinprodukter
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
FI903753A0 (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara halvsyntetiska gangliosidderivat.
FR2375211A1 (fr) Nouveaux acides sulfamoylbenzoiques, leur preparation et leur application en tant que medicaments
EA199800368A1 (ru) Новые промежуточные продукты и их использование для получения n,n'-мостиковых бисиндолилмалеимидов

Legal Events

Date Code Title Description
ST Notification of lapse